Overview
Founded in 2012 in Belgium, CluePoints applies advanced statistics and machine learning to the problem of data integrity in clinical trials. Pharmaceutical and biotech companies, as well as contract research organizations, use the platform to identify risks, track ongoing issues, and monitor discrepancies throughout the drug development process.
By the time of its EQT transaction, CluePoints had more than 9,500 platform users, had helped de-risk more than 1,600 studies, and detected over 142,000 data issues for its customers. The company's customer base includes many of the top 20 largest pharmaceutical companies globally.
Summit Partners made a significant growth investment in CluePoints in 2020. In June 2024, EQT's Healthcare Growth Strategy and EQT Growth Fund agreed to acquire a majority stake in CluePoints, with meaningful reinvestment from management and existing shareholders Summit Partners and co-founder Clinimetrics SA. The EQT deal marked CluePoints as one of the more notable Belgian healthtech exits of 2024.
Funding history
- Growth investment by Summit Partners2020
- Majority acquisition by EQTJune 2024EQT Healthcare Growth Strategy, EQT Growth Fund
Key people
In the news
- Throughout October, our team in Belgium took on a month of health challenges in support of Think Pink and the fight against breast cancer. 🎗️ What the team accomplished: → €20,000 raised for Think Pink → 6,725 km walked → 3,046 health challenges completed → 357 boosts of encouragement shared between teams The bigger win was the conversation. For a month, health and prevention became something colleagues talked about together every day. Breast cancer is the most common cancer among women worldwide, and early detection makes a real
- A special thank you to Brian Barnes of BioNTech and Cris McDavid of Parexel for joining RBQMLive 2026! “Trusted AI in Clinical Operations: From Automation to Decision Intelligence” explores how organizations are implementing AI responsibly in regulated clinical processes, from governance and validation to auditability and what sponsors need from their AI vendors. Missed the session or want to revisit it? Watch the full session on-demand here: https://hubs.ly/Q04DqkDM0.. #RBQMLive #RBQM #ClinicalTrials
- Agents in Practice: A Governed Approach to Agentic AI in Clinical Oversight” is now available on demand. Agentic AI has the potential to help clinical teams move more efficiently from data and insights to decisions and actions. But real-world adoption depends on how these capabilities are governed, traced and integrated into clinical workflows. In this session, Usama D., Chief Product and Technology Officer; Richard Young, Chief Strategy Officer; and Richard Davies, Principal Solutions Consultant, share CluePoints’ approach,
- One week until The Rise of the “Data-Pilot.” Most trial teams aren’t short on data or dashboards. What they’re missing is a fast answer to three questions: which signals matter, who should act, and when. On Nov 10, Richard Young, Zabir Macci and Juan Munoz-Pujol will show how an AI-powered Clinical Data Control Tower answers those questions, and what changes for the Data Managers running it. → The shift from data review to directed intelligence → How APIs, RBQM and AI connect eSource, labs and EDC into one decision layer → Where
- One week until The Rise of the “Data-Pilot.” Most trial teams aren’t short on data or dashboards. What they’re missing is a fast answer to three questions: which signals matter, who should act, and when. On Nov 10, Richard Young, Zabir Macci and Juan Munoz-Pujol will show how an AI-powered Clinical Data Control Tower answers those questions, and what changes for the Data Managers running it. → The shift from data review to directed intelligence → How APIs, RBQM and AI connect eSource, labs and EDC into one decision layer → Where
- Happy Halloween from the CluePoints team! #CluePoints #LifeatCluePoints
- We're proud to share that CluePoints has been named a finalist in the Data Analytics/Business Intelligence category at the 2026 Fierce Life Sciences Events Innovation Awards. This recognition reflects our new approach to clinical data review. This year, we expanded the statistical approach at the core of our RBQM software with three complementary capabilities: Intelligent Query Detection (IQD), Medical and Safety Review (MSR) and Intelligent Medical Coding (IMC). These extend the proven statistical engine and site oversight
- Regulators are backing real-time, continuous data review. Adding another dashboard for every review function won’t get sponsors there. In a new Contract Pharma piece, Kyle Given, RBQM Market Owner & Strategy Lead at CluePoints, explains why clinical data review stays fragmented. Queries, protocol deviations, KRIs, medical review, and statistical signals each sit with a different team and a different dashboard, so the same site issue gets raised several times, or missed entirely. Kyle’s case for a better approach: → Move from separate
Open roles
- Clinical Data Insights AnalystOct 12, 2026
- Director, Product MarketingJun 26, 2025
Alumni 4 went on to found or lead
Gregoire De HemptinneCTO and Software architect→Co-founder and CEO at Shayp
Laurent BRISBOISBackend Software Engineer→Co-Founder at Hubbiz
Luca DerumierMachine Learning Engineer→Co-Founder at Codika
Quentin DugauthierIT Coordinator→Chief Operating Officer at Digazu - PipeStore
Something wrong or missing? Send an update. Fixed within 24 hours.